177 related articles for article (PubMed ID: 15036196)
21. Isolated hepatic perfusion with high-dose melphalan for the treatment of colorectal metastasis confined to the liver.
Rothbarth J; Pijl ME; Vahrmeijer AL; Hartgrink HH; Tijl FG; Kuppen PJ; Tollenaar RA; van de Velde CJ
Br J Surg; 2003 Nov; 90(11):1391-7. PubMed ID: 14598420
[TBL] [Abstract][Full Text] [Related]
22. Isolated organ perfusion does not result in systemic microembolization of tumor cells.
Wu PC; McCart A; Hewitt SM; Turner E; Libutti SK; Bartlett DL; Alexander HR
Ann Surg Oncol; 1999; 6(7):658-63. PubMed ID: 10560851
[TBL] [Abstract][Full Text] [Related]
23. True versus mild hyperthermia during isolated hepatic perfusion: effects on melphalan pharmacokinetics and liver function.
Pilati P; Mocellin S; Rossi CR; Ori C; Innocente F; Scalerta R; Ceccherini M; Da Pian PP; Nitti D; Lise M
World J Surg; 2004 Aug; 28(8):775-81. PubMed ID: 15457357
[TBL] [Abstract][Full Text] [Related]
24. Isolated hepatic perfusion with high-dose melphalan results in immediate alterations in tumor gene expression in patients with metastatic ocular melanoma.
Varghese S; Xu H; Bartlett D; Hughes M; Pingpank JF; Beresnev T; Alexander HR
Ann Surg Oncol; 2010 Jul; 17(7):1870-7. PubMed ID: 20221901
[TBL] [Abstract][Full Text] [Related]
25. Isolated hepatic perfusion with tumor necrosis factor alpha and melphalan: experimental studies in pigs and phase I data from humans.
de Vries MR; Borel Rinkes IH; van de Velde CJ; Wiggers T; Tollenaar RA; Kuppen PJ; Vahrmeijer AL; Eggermont AM
Recent Results Cancer Res; 1998; 147():107-19. PubMed ID: 9670273
[TBL] [Abstract][Full Text] [Related]
26. The past decade of experience with isolated hepatic perfusion.
Grover A; Alexander HR
Oncologist; 2004; 9(6):653-64. PubMed ID: 15561809
[TBL] [Abstract][Full Text] [Related]
27. Isolated limb perfusion for unresectable melanoma of the extremities.
Noorda EM; Vrouenraets BC; Nieweg OE; van Geel BN; Eggermont AM; Kroon BB
Arch Surg; 2004 Nov; 139(11):1237-42. PubMed ID: 15545572
[TBL] [Abstract][Full Text] [Related]
28. A phase I study of hyperthermic isolated hepatic perfusion with oxaliplatin in the treatment of unresectable liver metastases from colorectal cancer.
Zeh HJ; Brown CK; Holtzman MP; Egorin MJ; Holleran JL; Potter DM; Bartlett DL
Ann Surg Oncol; 2009 Feb; 16(2):385-94. PubMed ID: 19034580
[TBL] [Abstract][Full Text] [Related]
29. Isolated hepatic perfusion with oxaliplatin combined with 100 mg melphalan in patients with metastases confined to the liver: A phase I study.
van Iersel LB; de Leede EM; Vahrmeijer AL; Tijl FG; den Hartigh J; Kuppen PJ; Hartgrink HH; Gelderblom H; Nortier JW; Tollenaar RA; van de Velde CJ
Eur J Surg Oncol; 2014 Nov; 40(11):1557-63. PubMed ID: 25125340
[TBL] [Abstract][Full Text] [Related]
30. Role of tumor necrosis factor on toxicity and cytokine production after isolated hepatic perfusion.
Lans TE; Bartlett DL; Libutti SK; Gnant MF; Liewehr DJ; Venzon DJ; Turner EM; Alexander HR
Clin Cancer Res; 2001 Apr; 7(4):784-90. PubMed ID: 11309322
[TBL] [Abstract][Full Text] [Related]
31. Tumor necrosis factor-alpha augments tumor effects in isolated hepatic perfusion with melphalan in a rat sarcoma model.
van Ijken MG; van Etten B; de Wilt JH; van Tiel ST; ten Hagen TL; Eggermont AM
J Immunother; 2000; 23(4):449-55. PubMed ID: 10916754
[TBL] [Abstract][Full Text] [Related]
32. Development of isolated hepatic perfusion for patients who have unresectable hepatic malignancies.
Jones A; Alexander HR
Surg Oncol Clin N Am; 2008 Oct; 17(4):857-76, x. PubMed ID: 18722923
[TBL] [Abstract][Full Text] [Related]
33. Hyperthermic pelvic perfusion with tumor necrosis factor-α for locally advanced cancers: encouraging results of a phase II study.
Bonvalot S; de Baere T; Mendiboure J; Paci A; Farace F; Drouard-Troalen L; Bonnet L; Hakime A; Bonniaud G; Raynard B; Israel P; Le Cesne A; Eggermont AM; Laplanche A; Muret J
Ann Surg; 2012 Feb; 255(2):281-6. PubMed ID: 22241290
[TBL] [Abstract][Full Text] [Related]
34. Isolated hepatic perfusion with 200 mg melphalan for advanced noncolorectal liver metastases.
van Iersel LB; Hoekman EJ; Gelderblom H; Vahrmeijer AL; van Persijn van Meerten EL; Tijl FG; Hartgrink HH; Kuppen PJ; Nortier JW; Tollenaar RA; van de Velde CJ
Ann Surg Oncol; 2008 Jul; 15(7):1891-8. PubMed ID: 18470571
[TBL] [Abstract][Full Text] [Related]
35. Chemosaturation Percutaneous Hepatic Perfusion: A Systematic Review.
Vogel A; Gupta S; Zeile M; von Haken R; Brüning R; Lotz G; Vahrmeijer A; Vogl T; Wacker F
Adv Ther; 2017 Jan; 33(12):2122-2138. PubMed ID: 27798773
[TBL] [Abstract][Full Text] [Related]
36. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
[TBL] [Abstract][Full Text] [Related]
37. Hyperthermic isolated liver perfusion with melphalan and bevacizumab.
Voron T; Zinzindohoué F; Journois D; Hervé C; Ponzio O; Lucas N
J Visc Surg; 2013 Feb; 150(1):60-6. PubMed ID: 23182850
[TBL] [Abstract][Full Text] [Related]
38. Hyperthermic isolated hepatic perfusion for the treatment of unresectable cancers confined to the liver.
Carroll NM; Alexander HR
J Surg Oncol; 2002 May; 80(1):64-5; author reply 66-7. PubMed ID: 11967911
[No Abstract] [Full Text] [Related]
39. Isolated hepatic perfusion with high-dose melphalan for the treatment of uveal melanoma metastases confined to the liver.
Noter SL; Rothbarth J; Pijl ME; Keunen JE; Hartgrink HH; Tijl FG; Kuppen PJ; van de Velde CJ; Tollenaar RA
Melanoma Res; 2004 Feb; 14(1):67-72. PubMed ID: 15091197
[TBL] [Abstract][Full Text] [Related]
40. Hyperthermic isolated limb perfusion with tumour necrosis factor-alpha and melphalan as palliative limb-saving treatment in patients with locally advanced soft-tissue sarcomas of the extremities with regional or distant metastases. Is it worthwhile?
Olieman AF; van Ginkel RJ; Molenaar WM; Schraffordt Koops H; Hoekstra HJ
Arch Orthop Trauma Surg; 1998; 118(1-2):70-4. PubMed ID: 9833110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
